Resolvyx Pharmaceuticals Stock

Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases.

Sign up today and learn more about Resolvyx Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Resolvyx Pharmaceuticals Stock

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Funding History

December 2005$17.0M
April 2008$25.0M
June 2010$1.2M
November 2010$2.5M


Member of the Board of Directors

Timothy J. Barberich

Chief Executive Officer

James Nichols


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: